Novartis Launches Phase III Trial For NSCLC Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
Called a potential blockbuster by Novartis, ASA404 will be tested in 1,200 patients to measure overall survival.
You may also be interested in...
Novartis Oncology Pipeline Has Lucky 13 Clinical Candidates
Novartis Institute for Biomedical Research's six-year-old mechanism-based research model is cranking out targeted cancer therapeutics, with three new molecules headed for the clinic by the end of 2008
Novartis Oncology Pipeline Has Lucky 13 Clinical Candidates
Novartis Institute for Biomedical Research's six-year-old mechanism-based research model is cranking out targeted cancer therapeutics, with three new molecules headed for the clinic by the end of 2008
Antisoma Buys Oncology Firm Xanthus
Through deal, Antisoma acquires Xanafide in Phase III for secondary AML and oral fludarabine, awaiting FDA approval.